Cargando…

Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis

Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin‐induced renal injury, there are no examples o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Masaya, Goda, Mitsuhiro, Maegawa, Akiko, Yoshioka, Toshihiko, Yoshida, Ami, Miyata, Koji, Aizawa, Fuka, Niimura, Takahiro, Hamano, Hirofumi, Okada, Naoto, Sakurada, Takumi, Chuma, Masayuki, Yagi, Kenta, Izawa‐Ishizawa, Yuki, Yanagawa, Hiroaki, Zamami, Yoshito, Ishizawa, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283743/
https://www.ncbi.nlm.nih.gov/pubmed/35445533
http://dx.doi.org/10.1111/cts.13282
_version_ 1784747393545142272
author Kanda, Masaya
Goda, Mitsuhiro
Maegawa, Akiko
Yoshioka, Toshihiko
Yoshida, Ami
Miyata, Koji
Aizawa, Fuka
Niimura, Takahiro
Hamano, Hirofumi
Okada, Naoto
Sakurada, Takumi
Chuma, Masayuki
Yagi, Kenta
Izawa‐Ishizawa, Yuki
Yanagawa, Hiroaki
Zamami, Yoshito
Ishizawa, Keisuke
author_facet Kanda, Masaya
Goda, Mitsuhiro
Maegawa, Akiko
Yoshioka, Toshihiko
Yoshida, Ami
Miyata, Koji
Aizawa, Fuka
Niimura, Takahiro
Hamano, Hirofumi
Okada, Naoto
Sakurada, Takumi
Chuma, Masayuki
Yagi, Kenta
Izawa‐Ishizawa, Yuki
Yanagawa, Hiroaki
Zamami, Yoshito
Ishizawa, Keisuke
author_sort Kanda, Masaya
collection PubMed
description Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin‐induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin‐induced renal injury, Library of Integrated Network‐based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin‐induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin‐induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin‐induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin‐induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin‐induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin‐induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary.
format Online
Article
Text
id pubmed-9283743
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92837432022-07-15 Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis Kanda, Masaya Goda, Mitsuhiro Maegawa, Akiko Yoshioka, Toshihiko Yoshida, Ami Miyata, Koji Aizawa, Fuka Niimura, Takahiro Hamano, Hirofumi Okada, Naoto Sakurada, Takumi Chuma, Masayuki Yagi, Kenta Izawa‐Ishizawa, Yuki Yanagawa, Hiroaki Zamami, Yoshito Ishizawa, Keisuke Clin Transl Sci Research Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin‐induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin‐induced renal injury, Library of Integrated Network‐based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin‐induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin‐induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin‐induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin‐induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin‐induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin‐induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary. John Wiley and Sons Inc. 2022-04-30 2022-07 /pmc/articles/PMC9283743/ /pubmed/35445533 http://dx.doi.org/10.1111/cts.13282 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Kanda, Masaya
Goda, Mitsuhiro
Maegawa, Akiko
Yoshioka, Toshihiko
Yoshida, Ami
Miyata, Koji
Aizawa, Fuka
Niimura, Takahiro
Hamano, Hirofumi
Okada, Naoto
Sakurada, Takumi
Chuma, Masayuki
Yagi, Kenta
Izawa‐Ishizawa, Yuki
Yanagawa, Hiroaki
Zamami, Yoshito
Ishizawa, Keisuke
Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
title Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
title_full Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
title_fullStr Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
title_full_unstemmed Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
title_short Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
title_sort discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283743/
https://www.ncbi.nlm.nih.gov/pubmed/35445533
http://dx.doi.org/10.1111/cts.13282
work_keys_str_mv AT kandamasaya discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT godamitsuhiro discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT maegawaakiko discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT yoshiokatoshihiko discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT yoshidaami discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT miyatakoji discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT aizawafuka discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT niimuratakahiro discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT hamanohirofumi discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT okadanaoto discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT sakuradatakumi discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT chumamasayuki discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT yagikenta discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT izawaishizawayuki discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT yanagawahiroaki discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT zamamiyoshito discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis
AT ishizawakeisuke discoveryofpreventivedrugsforcisplatininducedacutekidneyinjuryusingbigdataanalysis